Dose Escalation Using Hypoxia-adjusted Radiotherapy
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorRajiv Gandhi Cancer Institute & Research Center, India
About this trial
DE-HyART is a phase II clinical trial aimed at understanding the effects of escalating radiation doses to hypoxic sub-volumes inherent to squamous cell head and neck cancer. The study is aimed at assessing locoregional control, feasibility, and acceptable toxicity with such a strategy.
Eligibility criteria
Qualifiers
Age: 18 - 70 years
Willingness to sign informed consent (written/video documentation)
Performance status: ECOG 0 - 2
Histology proved - squamous cell carcinoma
Disqualifiers
HPV (p16) positive tumours
Prior surgery and/or radiation therapy given for any HNC
T1/T2 Glottis
Metastatic disease or disease not amenable for definitive locoregional treatment.
Trial design
Treatments tested in this trial
- DE-HyART
- Standard Arm
- Cisplatin injection
- Standard fractionation (Radiation Oncology preference)
Treatment groups
124 Participants
are divided into 3 treatment groupsSponsors and collaborators
Rajiv Gandhi Cancer Institute & Research Center, India
Lead sponsor
Varian, a Siemens Healthineers Company
Collaborator
Source ClinicalTrials.gov